Abstract
Eighty-four consecutive subjects with nonalcoholic fatty liver disease (NAFLD) were tested for non-organ-specific autoantibodies (NOSA) by indirect immunoflorescence. Indices of insulin resistance and biochemical and anthropometric parameters were assessed. The overall prevalence of anti-nuclear-antibodies (ANA), smooth muscle antibodies (SMA) and anti-mitochondrial-antibodies (AMA) was 35.7% (30/84), 18 subjects (21.4%) being positive for ANA, 4 (4.7%) for SMA, 6 for ANA and SMA, and 2 for AMA. NOSA-positive subjects were older (P < 0.01) and mostly females (63.3%). No significant difference was found in the age-corrected parameters studied, except for copper and ceruloplasmin, which was more elevated in NOSA-positive patients. The subset of high titer (≥1:100) ANA-positive patients had significantly (P < 0.05) greater insulin resistance than ANA-negative patients. In contrast, SMA-positive patients had higher gammaglobulin and significantly lower insulin resistance as compared to high-titer ANA-positive patients. In 3 NOSA-positive but not in NOSA-negative patients, liver biopsy disclosed features of overlapping NASH with autoimmune hepatitis, partially responding to diet combined with steroid treatment. In conclusion, NOSA positivity in NAFLD is more prevalent than in the general population. High-titre ANA but not SMA positivity is associated with insulin resistance.
Similar content being viewed by others
References
Czaja AJ: Autoantibodies. Baillieres Clin Gastroenterol 9:723-744, 1995
Lenzi M, Bellentani S, Saccoccio G, Muratori P, Masutti F, Muratori L, Cassani F, Bianchi FB, Tiribelli C, Prevalence of non-organ specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dyonisos cohort. Gut 45:435-441, 1999
Czaja AJ, Carpenter HA, Santrach PJ, Moore B: Genetic predisposition for immunologic features in chronic liver diseases other than autoimmune hepatitis, J Hepatol 24:52-59, 1996
Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 346:1221-1231, 2002
Day CP: Non-alcoholic steatohepatits (NASH): where are we now and where we going? Gut 50:585-588, 2002
Clark JM, Brancati FL, Diehl AM: Nonalcoholic fatty liver disease. Gastroenterology 122:1649-1657, 2002
Lonardo A, Loria P, Carulli N: Insulin resistance in non-alcoholic fatty liver disease. In Steatohepatitis (NASH and ASH). U Leuschner, O James, H Dancygier (eds). Dordrecht, Kluwer Academic Publishers, 2001, pp. 104-113
Marchesini G, Forlani G: NASH: from liver diseases to metabolic disorders and back to clinical hepatology. Hepatology 35:497-499, 2002
Festa A, D'Agostino R, Howard G, Mykkänen L, Tracy RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome. The insulin resistance atherosclerosis study (IRAS). Circulation 102:42-47, 2000
Fröhlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, Muche R, Brenner H, Koenig W: Association between C-reactive protein and features of the metabolic syndrome. Diabetes Care 23:1835-1839, 2000
Tajiri K, Takenawa H, Yamaoka K, Yamane M, Marumo F, Sato C: Nonalcoholic steatohepatitis masquerading as autoimmune hepatitis. J Clin Gastroenterol 25:538-540, 1997
Tumiel M, Whitcomb BJ, Krawitt EL: Circulating antinuclear antibodies in patients with nonalcoholic steatohepatitis. Hepatology 20:409A, 1249, 1994; (abstract)
Caldwell SH, Oelsner DH, Jezzoni JC, Hesenheide EE, Battle EH, Driscoll CJ: Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 29:664-669, 1999
Bacon BR, Farawash MJ, Janney CG, Neuschwander-Tetri BA: Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 107:1103-1109, 1994
Neuschwander-Tetri BA, Caldwell SH: Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 37:1202-1219, 2003
Lonardo A, Loria P, Leonardi F, Borsatti A, Neri P, Pulvirenti M, Verrone AM, Bagni A, Bertolotti M, Ganazzi D, Carulli N: Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case—control study. Dig Liver Dis 34:204-211, 2002
Bravo AA, Sheth SG, Chopra S: Liver biopsy. N Engl J Med 344:495-500, 2001
Johnson PJ, McFarlane IG: Meeting report: International Autoimmune Hepatitis Group. Hepatology 18:998-1005, 1993
Cassani F, Bianchi FB, Lenzi M, Volta U, Pisi E: Immunomorphological characterisation of antinuclear antibodies in chronic liver disease. J Clin Pathol 38:801-805, 1985
Cassani F, Fusconi M, Bianchi FB, Selleri L, Baffoni L, Lenzi M, Pisi E: Precipitating antibodies to rabbit thymus extractable antigens in chronic liver disease: relationship with antiactin antibodies. Clin Exp Immunol 68:588-595, 1987
Fusconi M, Baum H, Caselli A, Cassani F, Ballardini G, Lenzi M, Volta U, Zauli D, Bianchi FB: Demonstration of peptide-specific and cross-reactive epitopes in proteins reacting with antimitochondrial antibodies of primary biliary cirrhosis. J Hepatol 15:162-169, 1992
Brunt E, Janney C, Di Bisceglie A, Neuschwander-Tetri B, Bacon B: Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94:2467-2474, 1999
Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WGE, Czaja AJ, Desmet VJ, Donaldson PT, Eddleston ALWF, Fainboim L, Heathcote J, Homberg JC, Hoofnagle JH, Kakumu S, Krawitt EL, Mackay IR, MacSween RNM, Maddrey WC, Manns MP, McFarlane IG, Meyerzum Büschenfelde K-H, Miell-Vergani G, Nakanuma Y, Nishioka M, Penner E, Porta G, Portmann BC, Reed WD, Rodes J, Schalm SW, Scheuer PJ, Schrumpf E, Seki T, Toda G, Tsuji T, Tygstrup N, Vergani D, Zeniya M: International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31:929-938, 1999
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ: Quantitative Insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85:2402-2410, 2000
Abbasi F, Reaven GM: Evaluation of the quantitative insulin sensitivity check index as an estimate of insulin sensitivity in humans. Metabolism 51:235-237, 2002
Dixon JB, Bhatal PS, O'Brien PE: Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121:91-100, 2001
Valenti L, Fracanzani AL, Dongiovanni P, Santorelli G, Branchi A, Taioli E, Fiorelli G, Fargion S: Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 122:274-280, 2002
Haffner SM, Miettinen H, Stern MP: The homeostasis model in the San Antonio Heart study. Diabetes Care 20:1087-1092, 1997
Laroussi N, Mosnier JF, Morel Y, Deugnier Y, Dumas O, Audigier JC: Non alcoholic steatohepatitis: a multifactorial, frequent, paucysymptomatic liver disease with a fibrotic outcome. Gastroenterol Clin Biol 26:475-479, 2002
De Jorge FB: Correlation between copper and transaminases in the blood serum in infectious hepatitis, during convalescence. Clin Chim Acta 20:111-112, 1968
Marniemi J, Jarvisalo J, Toikka T, Raiha I, Ahotupa M, Sourander L: Blood vitamins, mineral elements and inflammation markers as risk factors of vascular and non-vascular disease mortality in an elderly population. Int J Epidemiol 27:799-807, 1998
Niskanen J, Marniemi J, Piironen O, Maatela J, Maki J, Vuori I, Seppanen A, Kallio V, Aromaa A: Trace element levels in serum and urine of subjects died of coronary heart disease. Acta Pharmacol Toxicol 59(suppl VII):340-343, 1986
Reunanen A, Knekt P, Marniemi J, Maki J, Maatela J, Aromaa A: Serum calcium, magnesium, copper and zinc and risk of cardiovascular death. Eur J Clin Nutr 50:431-437, 1996
Cousins RJ: Absorption, transport, and hepatic metabolism of copper and zinc: special reference to metallothionein and ceruloplasmin. Physiol Rev 65:238-309, 1985
Natesha RK, Natesha R, Victory D, Barnwell SP, Hoover EL: A prognostic role for ceruloplasmin in the diagnosis of indolent and recurrent inflammation. J Natl Med Assoc 84:781-784, 1992
Hsieh SD, Yoshinaga H, Muto T, Sakurai Y: Regular physical activity and coronary risk factors in Japanese men. Circulation 97:661-665, 1998
Czaja AJ: Autoantibodies in liver disease. Gastroenterology 120:239-249, 2001
Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC: Non-alcoholic fatty liver disease, another feature of the metabolic syndrome? Clin Nutr 18:253-258, 1999
Forouhi NG, Sattar N, McKeigue PM: Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. Int J Obes 25:1327-1331, 2001
Hay JE, Czaja AJ, Rakela J, Ludwig J: The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. Hepatology 9:193-197, 1989
Knobler H, Schattner A, Zhornicki T, Malnick SD, Keter D, Sokolovskaya N, Lurie Y, Bass: Fatty liver. An additional and treatable feature of the insulin resistance syndrome. Q J Med 92:73-79, 1999
Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N: Metformin in nonalcoholic steatohepatitis. Lancet 358:893-894, 2001
Facchini FS, Hua NW, Stoohs RA: Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 122:931-939, 2002
Fargion S, Mattioli M, Fracanzani AL, Sampietro M, Tavazzi D, Fociani P, Taioli E, Valenti L, Fiorelli G: Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 96:2448-2455, 2001
Tazawa Y, Noguchi H, Nishinomiya F, Takada G: Effect of weight changes on serum transaminase activities in obese children. Acta Paediatr Jpn 39:210-214, 1997
Loguercio C, De Girolamo V, de Sio I, Tuccillo C, Ascione A, Baldi F, Budillon G, Cimino L, Di Carlo A, Di Marino MP, Morisco F, Picciotto F, Terracciano L, Vecchione R, Verde V, Del Vecchio Blanco C: Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects. J Hepatol 35:568-574, 2001
Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, McGill DB: Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 23:1464-1467, 1996
Joshi S, Cauch-Dudek K, Wanless IR, Lindor KD, Jorgensen R, Batts K, Heathcote EJ: Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology 35:409-413, 2002
Nakamura K, Yoneda M, Yokohama S, Tamori K, Sato Y, Aso K, Aoshima M, Hasegawa T, Makino I: Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 13:490-495, 1998
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Loria, P., Lonardo, A., Leonardi, F. et al. Non-Organ-Specific Autoantibodies in Nonalcoholic Fatty Liver Disease: Prevalence and Correlates. Dig Dis Sci 48, 2173–2181 (2003). https://doi.org/10.1023/B:DDAS.0000004522.36120.08
Issue Date:
DOI: https://doi.org/10.1023/B:DDAS.0000004522.36120.08